Entera Bio Nears Major Catalyst with EB613, Eyeing Breakout
AI Prediction of Entera Bio Ltd. (ENTX)
Entera Bio is positioned for significant growth with its lead asset, EB613, approaching a critical regulatory phase, which could drive its stock price up.
Entera Bio, a clinical-stage biopharmaceutical company, is at a pivotal juncture with its lead product, EB613, designed for the treatment of postmenopausal osteoporosis. The company anticipates receiving FDA feedback on its Phase 3 protocol soon, which could potentially streamline the path to commercialization. This comes amid a broader industry context where oral alternatives to injectable treatments are highly sought after, positioning EB613 as a potential game-changer in osteoporosis treatment. The upcoming FDA feedback and the initiation of Phase 3 trials represent critical catalysts that could significantly impact the company's valuation and stock price in the near future.
ENTX Report Information
Prediction Date2026-04-03
Close @ Prediction$1.26
Mkt Cap81m
IPO DateN/a
AI-derived Information
Recent News for ENTX
- Jul 8, 9:16 am — America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) (FinanceWire)
- Jun 22, 2:29 pm — ENTX Stock On Track For Best Day In Over 5 Years Whats Driving The Rally? (Stocktwits)
- Jun 22, 8:30 am — Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis (GlobeNewswire RSS)
- Jun 16, 8:33 am — Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 (GlobeNewswire RSS)
- Jun 15, 8:45 am — ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) (GlobeNewswire RSS)
- May 28, 8:50 am — Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation (GlobeNewswire RSS)
- May 8, 4:05 pm — Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs (GlobeNewswire RSS)
- Apr 6, 1:50 pm — Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners (PR Newswire)
- Mar 27, 4:05 pm — Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
- Mar 4, 8:30 am — Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis (GlobeNewswire)
- Feb 26, 8:00 am — Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
- Feb 19, 1:49 am — What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours (Benzinga)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest